adavosertib (AZD1775) / Merck (MSD), AstraZeneca  >>  Phase 1
Welcome,         Profile    Billing    Logout  

32 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
adavosertib (AZD1775) / AstraZeneca
MK1775-005, NCT01047007: A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Terminated
1
11
NA
adavosertib 20 mg, MK-1775, 5-FU 1000 mg/m^2/day, CDDP, Cisplatin, adavosertib 65 mg
Merck Sharp & Dohme LLC
Solid Tumors
06/11
06/11
MK-1775-001, NCT00648648: A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors

Completed
1
206
NA
adavosertib, MK-1775, gemcitabine, cisplatin, carboplatin
Merck Sharp & Dohme LLC
Solid Tumors
01/14
01/14
NCT01925326: A Study of MK-1775 in Combination With Cisplatin and Radiation in Cervical Cancer

Not yet recruiting
1
57
Canada
MK-1775, Cisplatin, Platinol, External beam pelvic radiation and brachytherapy
University Health Network, Toronto
Epithelial Cervical Cancer
09/15
03/16
NCT02207010: A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Completed
1
20
US
AZD1775, Wee1 inhibitor, MK1775
St. Joseph's Hospital and Medical Center, Phoenix, The Ben & Catherine Ivy Foundation, American Society of Clinical Oncology, Barbara Ann Karmanos Cancer Institute, Translational Genomics Research Institute
Glioblastoma, GBM
12/15
03/19
NCT02341456: Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Completed
1
19
Japan, RoW
AZD1775, MK1775, Paclitaxel, carboplatin
AstraZeneca
Advanced Solid Tumours
12/16
07/18
NCT02482311: Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Completed
1
92
Canada, US
AZD 1775
AstraZeneca
Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
01/18
08/19
NCT03315091: Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours

Completed
1
31
Europe
Treatment A - AZD1775 administered under fasted conditions, Treatment B - AZD1775 administered under fed conditions.
AstraZeneca, Quintiles, Inc.
Solid Tumours
04/18
04/18
NCT02508246: WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

Completed
1
12
US
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery, WEE1 Inhibitor AZD1775, AZD-1775, AZD1775, MK-1775, MK1775
University of Washington, National Cancer Institute (NCI)
Head and Neck Squamous Cell Carcinoma
04/18
04/18
NCT02610075: Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Completed
1
62
US
AZD1775
AstraZeneca
Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer
04/18
04/18
NCT02381548: Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Terminated
1
20
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Belinostat, Beleodaq, PXD 101, PXD101, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
05/18
05/18
NCT01916551: A Dose Escalation Trial of Wee1 Inhibitor MK1775

Not yet recruiting
1
70
US
Gemcitabine, Gemzar, MK-1775, Wee1 inhibitor, Radiation, IMRT
University of Michigan Cancer Center
ADENOCARCINOMA OF THE PANCREAS
10/18
10/19
NCT03333824: Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Completed
1
33
US
CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775
AstraZeneca, Quintiles, Inc.
Solid Tumours
01/19
01/19
REFMAL 412, NCT02617277: Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Active, not recruiting
1
56
US
AZD1775, Adavosertib, MEDI4736, Durvalumab
AstraZeneca
Advanced Solid Tumours
04/19
12/24
NCT02511795: AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Checkmark In combination with AZD1775
Mar 2019 - Mar 2019: In combination with AZD1775
Checkmark Lynparza + AZD1775 combination in solid tumors at ASCO 2016
Jun 2016 - Jun 2016: Lynparza + AZD1775 combination in solid tumors at ASCO 2016
Checkmark ASCO 2016
More
Completed
1
128
Canada, US
AZD1775, Olaparib
AstraZeneca
Refractory Solid Tumours, Relapsed Small Cell Lung Cancer (SCLC)
04/19
10/19
NCT03313557: AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

Completed
1
48
US, Europe
Wee-1 kinase inhibitor AZD1775
AstraZeneca, Quintiles, Inc.
Solid Tumors
05/19
05/19
NCT02791919: Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Withdrawn
1
0
NA
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Filgrastim, Filgrastim XM02, Filgrastim-sndz, G-CSF, Neupogen, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, rG-CSF, Tbo-filgrastim, Tevagrastim, Zarxio, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Laboratory Biomarker Analysis, Pharmacological Study, WEE1 Inhibitor AZD1775, AZD-1775, AZD1775, MK-1775, MK1775
National Cancer Institute (NCI)
CNS 2a, CNS 2b, CNS 2c, CNS1, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
05/19
05/19
NCT02585973: Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Completed
1
12
US
AZD1775, MK-1775 hemihydrate, L001739996-008U, Cisplatin, cisplatin injection, Intensity Modulated Radiotherapy Treatments, IMRT
UNC Lineberger Comprehensive Cancer Center, AstraZeneca
Carcinoma, Squamous Cell of Head and Neck
06/19
06/21
WISTERIA, NCT03028766: WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer

Completed
1
9
Europe
AZD1775, Cisplatin, Radiotherapy, IMRT
University of Birmingham, AstraZeneca, Cancer Research UK
Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Larynx Cancer
10/19
02/21
NCT02906059: Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Completed
1
7
US
AZD1775, Irinotecan, Camptosar, Campto
NYU Langone Health, AstraZeneca
Metastatic Colorectal Cancer
03/20
03/20
BISCAY, NCT02546661 / 2015-002228-25: Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Hourglass Mar 2020 - Mar 2020 : Completion of P1 trial in 2nd+ line muscle invasive metastatic bladder cancer
Checkmark From BISCAY trial for muscle-invasive bladder cancer
Sep 2019 - Sep 2019: From BISCAY trial for muscle-invasive bladder cancer
Active, not recruiting
1
156
Europe, Canada, US
AZD4547, MEDI4736, Durvalumab, Olaparib, Lynparza, AZD1775, Vistusertib, AZD9150, Selumetinib
AstraZeneca
Muscle Invasive Bladder Cancer
03/20
06/24
NCT01748825: AZD1775 for Advanced Solid Tumors

Completed
1
67
US
MK-1775 (AZD1775), Adavosertib
National Cancer Institute (NCI)
Solid Tumors
05/20
05/20
NCT01922076: Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Completed
1
46
Canada, US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Laboratory Biomarker Analysis, Pharmacological Study, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Gliosarcoma
12/20
09/22
NCT01958658: AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer

Suspended
1
57
Canada
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiotherapy, External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Internal Radiation Therapy, BRACHYTHERAPY, internal radiation, Internal Radiation Brachytherapy, radiation brachytherapy, Laboratory Biomarker Analysis, Pharmacological Study, Pulsed-Dose Rate Brachytherapy, WEE1 Inhibitor AZD1775, AZD-1775, AZD1775, MK-1775, MK1775
National Cancer Institute (NCI)
Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer
06/21
 
NCT01849146: Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Active, not recruiting
1
74
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI)
Glioblastoma, Recurrent Glioblastoma
07/21
03/25
NCT04462952: Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Completed
1
6
Japan
Adavosertib (AZD1775)
AstraZeneca
Advanced Solid Tumours
09/21
09/21
ADME, NCT05008913: Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib

Terminated
1
2
Europe
[14C]Adavosertib, AZD1775
AstraZeneca, Parexel
Advanced Solid Tumors
11/21
11/21
NCT04949425: A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Terminated
1
3
Europe, US
Adavosertib, AZD1775
AstraZeneca, Parexel
Advanced Solid Tumours
04/22
04/22
NCT03345784: Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Terminated
1
10
Canada, US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation
National Cancer Institute (NCI)
Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma, Stage I Uterine Corpus Cancer AJCC v7, Stage I Vaginal Cancer AJCC v6 and v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Cervical Cancer AJCC v6 and v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Cervical Cancer AJCC v6 and v7, Stage III Uterine Corpus Cancer AJCC v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIA Cervical Cancer AJCC v6 and v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Vaginal Carcinoma
05/22
05/22
NCT04959266: A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

Terminated
1
5
Europe, US
Adavosertib, Itraconazole, Rifampicin, Omeprazole
AstraZeneca, Parexel
Advanced Solid Tumours
06/22
06/22
NCT04197713: Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Checkmark Results from combination of Olaparib followed by adavosertib for advanced solid tumors with selected mutations and PARP resistance
Nov 2022 - Nov 2022: Results from combination of Olaparib followed by adavosertib for advanced solid tumors with selected mutations and PARP resistance
Active, not recruiting
1
16
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
02/23
09/24
NCT02659241: Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
1
38
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Laboratory Biomarker Analysis
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Carcinomatosis, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
12/26
12/26
NCT04460937: Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Active, not recruiting
1
33
US
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Distal Esophagus Adenocarcinoma, Gastric Cardia Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Esophageal Adenocarcinoma, Unresectable Esophageal Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
10/24
10/24

Download Options